Safety Assessment of Biological Products A Regulatory Perspective
PL-2 Safety Assessment of Biological Products A Regulatory Perspective
出处
《毒理学杂志》
CAS
CSCD
北大核心
2005年第A03期173-173,共1页
Journal of Toxicology
-
1poors John Rietveld Ad.Orphan and Rare Disease Products -The Payer Perspective[J].Journal of Pharmacy and Pharmacology,2014,2(9):541-550.
-
2庄嬿嬿.阿立哌唑与奥氮平治疗精神分裂症的应用效果对比研究[J].海峡药学,2016,28(12):124-125. 被引量：6
-
3吴静.环磷腺苷葡胺治疗慢性充血性心力衰竭临床研究[J].国外医药（抗生素分册）,2016,37(3):141-143. 被引量：2
-
4Somaia Said Abd E1-Karim Magdy Ibrahim E1-Zahar Manal Mohamed Anwar.Nanotechnology in Cancer Diagnosis and Treatment[J].Journal of Pharmacy and Pharmacology,2015,3(7):299-315. 被引量：1
-
5ZHANGXiang-lin,ValerioReggi,VittorioBertele＇.Regulatory evaluation of efficacy and safety of new drugs in China[J].Chinese Medical Journal,2004,17(2):320-320.
-
6Chun-jian LI Jun HUANG Zhi-jian YANG Ke-jiang CAO.Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits[J].Acta Pharmacologica Sinica,2007,28(1):58-65. 被引量：1
-
7Aimin Shi,Brenda Tiffin,Quoia Chen.The Trend of Global Harmonization of Regulatory Tests & Guidelines[J].毒理学杂志,2005,19(A03):174-174.
-
8加拿大批准Ralivia治疗中重度疼痛[J].齐鲁药事,2008,27(9):515-515.
-
9张良,蒲旭峰,张德波.注射用头孢地嗪钠生物安全性检查标准研究[J].成都医学院学报,2014,9(3):281-285. 被引量：1
-
10Pharmacology in PBL Teaching： a Hong Kong Perspective[J].中国药理通讯,2007,24(4):51-52.
